Century Therapeutics, Inc. (IPSC) Valuation

Valuation

Model-based estimates, not advice. The DCF is the discounted-cash-flow value per share; compare it with the price, not as a target.

DCF fair value

+85.0%

$2.74

vs $1.48 price

Levered DCF

-$31.93

After debt service

Piotroski score

1 / 9

Weak

Altman Z-score

-1.94

Distress zone

Rating

Overall 2 / 5

Ratios by fiscal year

Margins and yields are shares of revenue, equity or price; multiples are ×.

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019
P/E	-9.04×	-0.63×	-1.44×	-2.26×	-9.11×	-22.83×	-5.08×
P/B	0.54×	0.49×	1.07×	0.98×	2.2×	-11.76×	-13.63×
P/S	0.79×	12.06×	88.11×	56.99×	0×	0×	0×
EV / EBITDA	19.64×	-0.67×	-1.63×	-2.16×	-9.27×	-24.06×	-4.94×
Gross margin	88.0%	100.0%	100.0%	100.0%	0.0%	0.0%	0.0%
Operating margin	-13.8%	-2096.5%	-6556.9%	-2574.2%	0.0%	0.0%	0.0%
Net margin	-8.8%	-1920.9%	-6115.1%	-2518.4%	0.0%	0.0%	0.0%
Current ratio	5.97×	1.5×	9.92×	10.72×	14.57×	6.51×	28.1×
Debt / equity	0.27×	0.33×	0.26×	0.16×	0.06×	-0.2×	0×
Interest coverage	0×	0×	-271.38×	0×	-74.42×	-129.07×	0×
Dividend yield	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Payout ratio	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

Key metrics by fiscal year

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019
Return on equity	-6.0%	-78.4%	-74.0%	-43.2%	-24.2%	50.3%	266.5%
Return on invested capital	-7.2%	-60.5%	-42.6%	-28.9%	-22.4%	-51.8%	-22.8%
Return on assets	-4.3%	-35.8%	-37.9%	-26.9%	-21.9%	-50.2%	-269.3%
Free cash flow yield	-121.6%	-138.8%	-51.8%	-5.6%	-15.4%	-4.1%	-1.5%
Earnings yield	-11.1%	-159.3%	-69.4%	-44.2%	-11.0%	-4.3%	-19.6%
Enterprise value	$67.8M	$74.8M	$197.8M	$261.4M	$841.1M	$1.2B	$1.2B
Net debt / EBITDA	-5.3×	0.04×	-0.01×	0.29×	0.35×	0.11×	0.18×
Cash conversion cycle (days)	-131	84	109	55	-605	-1,682	-2,269